This investigation aimed to create a new nomogram based on complement C3 to forecast 1-, 3-, and 5-year overall survival (OS) rates in patients with early-stage hepatocellular carcinoma (HCC) exhibiting microvascular invasion (MVI) post-curative surgery. The gene discussed is C3; the disease is hepatocellular carcinoma.